Tenaya Therapeutics, Inc.
NASDAQ:TNYABiotechnology
-$0.00 today
- Market cap
- $69.95M
- Beta
- 2.82
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$0.54
Volume 2.77M
Average 3.79M
TNYA EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Tenaya Therapeutics, Inc.NASDAQ: TNYA
EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026
EPS (Basic) remains negative
Q1 FY2026 EPS (Basic) was -$0.09, compared with -$0.24 a year earlier. Trailing-twelve-month EPS (Basic) was -$0.47.
Context
- EPS (Basic) grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 6 analysts of -$0.4 (+32.4%) for the fiscal year ending Dec 2026, a slowdown from the +55.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.09+25.0% QoQ
- Last fiscal yearDec 2025
- -$0.59+55.0% YoY
- LTMMar 2026
- -$0.47+59.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +62.5% | +54.1% | -8.4 pp |
| 1 year | +55.0% | +32.4% | -22.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (0.59) USD
- Year-over-year change
- +55.0%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (0.59) | +55.0% |
| FY2024 | 2024-12-31 | (1.31) | +22.0% |
| FY2023 | 2023-12-31 | (1.68) | +39.1% |
| FY2022 | 2022-12-31 | (2.76) | -63.3% |
| FY2021 | 2021-12-31 | (1.69) | — |
EPS (Basic) vs competitors
How TNYA compares with its peers on the latest reported figures
- TNYA's LTM Mar 2026 EPS (Basic) of -$0.47 is the 3rd highest of the 11 companies compared; the peer median is -$1.17.
- Its year-over-year change of +59.5% is the 2nd highest of 11, against a peer median of +15.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $1.28 | +241.2% | — | |
| LTM Mar 2026 | -$0.46 | +14.8% | — | |
| LTM Mar 2026 | -$0.47 | +59.5% | — | |
| LTM Mar 2026 | -$0.59 | +14.6% | — | |
| LTM Mar 2026 | -$1.06 | +37.3% | — | |
| LTM Mar 2026 | -$1.17 | +40.3% | — | |
| LTM Mar 2026 | -$1.17 | +14.6% | — | |
| LTM Mar 2026 | -$1.31 | +16.6% | — | |
| LTM Mar 2026 | -$1.42 | +12.3% | — | |
| LTM Mar 2026 | -$1.98 | -35.6% | — | |
| LTM Mar 2026 | -$2.74 | +39.6% | — | |
| Peer median (excluding TNYA) | -$1.17 | +15.7% | — | |
Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| Gross Profit | (4.03M) | (8.71M) | (8.69M) | (8.47M) | (8.44M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 54.39M | 94.54M | 98.04M | 86.74M | 68.61M |
| Selling, General & Admin | 14.39M | 22.37M | 24.47M | 20.74M | 24.72M |
| Operating Expenses | 68.78M | 116.91M | 122.51M | 107.48M | 84.9M |
| Depreciation & Amortization | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| EBITDA | (68.7M) | (114.95M) | (115.4M) | (102.66M) | (82.16M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (72.81M) | (125.62M) | (131.19M) | (115.95M) | (93.33M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 108K | 1.95M | 7.06M | 4.74M | 2.68M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 85K | 1.96M | 7.11M | 4.82M | 2.73M |
| Income Before Tax | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| EPS (Diluted) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| Weighted Avg Shares | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
| Weighted Avg Shares (Diluted) | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
Intrinsic Alpha fair value
Locked
Current Price
$0.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.